COCP Stock — Cocrystal Pharma Inc.: Cash, EV, Pipeline

Share price

$1.21

Market cap

$23.3M

Cash

$2.2M

Enterprise value

$21.1M

Balance sheet

Cash	$2.2M
Debt	$0.0M
Net cash	$2.2M
Enterprise value	$21.1M
Basic shares	13.8M shares
Fully diluted shares	22.2M shares
Fully diluted market cap	$26.9M
Cash per share	$0.16

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading COCP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Nov 12 - Dec 24	CDI-988	Phase 2	Norovirus	late 2026 or early 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CDI-988

Phase 1 · Active Modality: small molecule

Target 3CL protease

Indications

Norovirus (prevention and treatment) (Phase 1)

Status note Phase 1 SAD/MAD safety data reported (SAD Jul 2024/Jan 2025; MAD favorable Aug 2025). FDA Study May Proceed letter received Sep 2025; Phase 1b norovirus challenge study at Emory commenced with first subjects enrolled Mar 2026.

CC-42344

Phase 2 · Active Modality: small molecule

Target PB2

Indications

Influenza A (pandemic and seasonal) (Phase 2)

Status note Phase 2a human challenge study hampered by low infectivity and virology readout, hindering clinical endpoints; dispute with the UK CRO that performed the study. Program not explicitly discontinued.

CC-31244

Phase 2 · Active Modality: small molecule

Target NS5B

Indications

Hepatitis C (genotype 1) (Phase 2)

Status note Phase 2a completed 2017; company has been seeking a partner for further clinical development since. Not explicitly discontinued.

Influenza preclinical lead

Preclinical · Active Modality: small molecule

Target PB2

Indications

Influenza A (pandemic and seasonal) (Preclinical)

Status note Preclinical lead for oral or inhaled treatment of pandemic and seasonal influenza A; binds a highly conserved PB2 domain.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CDI-988
Lead indication	Norovirus
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07198139	Phase 2	Recruiting	Sponsor	COCP	—	Norovirus	late 2026 or early 2027

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Cocrystal Pharma, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

COCP — Cocrystal Pharma Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials